Overexpressed TcR-Vβs During the First 12 Months After Transplantation With FACS-Sorted CD34+ HPCs
Patient No. . | Pretransplant . | 1-2 mo . | 3-5 mo . | 6-12 mo . | ||||
---|---|---|---|---|---|---|---|---|
TcR-V . | % . | TcR-V . | % . | TcR-V . | % . | TcR-V . | % . | |
1 | —3-150 | Vβ 16 | 19.2 | — | Vβ 14 | 4.7 | ||
2 | — | Vβ 3 | 15.8 | Vβ 3 | 27.8 | Vβ 3 | 19.3 | |
Vβ 13.1 | 4.7 | Vβ 13.1 | 4.3 | Vβ 13.1 | 8.2 | |||
Vβ 16 | 3.8 | |||||||
Vβ 17 | 8.7 | |||||||
3 | — | Vβ 13.3 | 23.4 | ND3-151 | ND | |||
4 | — | — | — | Vβ 2 | 19.5 | |||
5 | Vβ 5.2 | 15.6 | Vβ 13.6 | 5.4 | ND | ND | ||
Vβ 17 | 8.28 | |||||||
6 | — | — | Vβ 8 | 15.2 | Vβ 13.1 | 3.7 | ||
Vβ 13.1 | 5.53 | |||||||
7 | — | Vβ 13.1 | 3.9 | Vβ 13.6 | 6.2 | Vβ 13.1 | 3.9 | |
Vβ 13.6 | 4.0 | Vβ 14 | 9.0 | |||||
Vβ 22 | 9.0 | |||||||
8 | — | — | — | Vβ 21.3 | 4.5 | |||
Vβ 22 | 9.5 | |||||||
9 | — | Vβ 12 | 4.7 | ND | ND | |||
Vβ 20 | 7.2 | |||||||
Vβ 21.3 | 4.1 |
Patient No. . | Pretransplant . | 1-2 mo . | 3-5 mo . | 6-12 mo . | ||||
---|---|---|---|---|---|---|---|---|
TcR-V . | % . | TcR-V . | % . | TcR-V . | % . | TcR-V . | % . | |
1 | —3-150 | Vβ 16 | 19.2 | — | Vβ 14 | 4.7 | ||
2 | — | Vβ 3 | 15.8 | Vβ 3 | 27.8 | Vβ 3 | 19.3 | |
Vβ 13.1 | 4.7 | Vβ 13.1 | 4.3 | Vβ 13.1 | 8.2 | |||
Vβ 16 | 3.8 | |||||||
Vβ 17 | 8.7 | |||||||
3 | — | Vβ 13.3 | 23.4 | ND3-151 | ND | |||
4 | — | — | — | Vβ 2 | 19.5 | |||
5 | Vβ 5.2 | 15.6 | Vβ 13.6 | 5.4 | ND | ND | ||
Vβ 17 | 8.28 | |||||||
6 | — | — | Vβ 8 | 15.2 | Vβ 13.1 | 3.7 | ||
Vβ 13.1 | 5.53 | |||||||
7 | — | Vβ 13.1 | 3.9 | Vβ 13.6 | 6.2 | Vβ 13.1 | 3.9 | |
Vβ 13.6 | 4.0 | Vβ 14 | 9.0 | |||||
Vβ 22 | 9.0 | |||||||
8 | — | — | — | Vβ 21.3 | 4.5 | |||
Vβ 22 | 9.5 | |||||||
9 | — | Vβ 12 | 4.7 | ND | ND | |||
Vβ 20 | 7.2 | |||||||
Vβ 21.3 | 4.1 |